ClinicalTrials.Veeva

Find clinical trials for Lung Cancer in Indianapolis, IN

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Non-Small-Cell Lung Carcinoma
Cancer
Carcinoma
Small Cell Lung Carcinoma
Squamous Cell Carcinoma of Head and Neck
Colorectal Cancer
Triple Negative Breast Cancer

Lung Cancer trials near Indianapolis, IN, USA:

EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer (KEYNOTE B36)

untreated for advanced or metastatic, PD-L1 positive non-small cell lung cancer (NSCLC). The primary objective is to evaluate the p...

Enrolling
Non-small Cell Lung Cancer
Drug: Pembrolizumab (MK-3475) 200 mg
Device: NovoTTF-200T

Phase 2

NovoCure
NovoCure

Indianapolis, Indiana, United States and 23 other locations

Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy (ADRIATIC)

This is a Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as...

Active, not recruiting
Small Cell Lung Cancer
Drug: Durvalumab
Other: Placebo

Phase 3

AstraZeneca
AstraZeneca

Muncie, Indiana, United States and 181 other locations

Locations recently updated

Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer (DeLLphi-304)

The main objective is to compare the efficacy of tarlatamab with standard of care (SOC) on prolonging overall survival (OS).

Enrolling
Small Cell Lung Cancer (SCLC)
Drug: Lurbinectedin
Drug: Topotecan

Phase 3

Amgen
Amgen

Indianapolis, Indiana, United States and 218 other locations

Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers

combination with pembrolizumab in participants with non-small cell lung cancer (NSCLC).Each treatment cycle lasts 21 days. Particip...

Enrolling
Lung Cancer Metastatic
Lung Cancer Stage IV
Drug: SLC-391
Biological: pembrolizumab

Phase 1, Phase 2

SignalChem Lifesciences

Indianapolis, Indiana, United States and 12 other locations

Temozolomide and Atezolizumab as Second or Third Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer

This phase II trial studies the effects of temozolomide and atezolizumab as second or third line treatment for patients with small cell lung ...

Enrolling
Stage IVA Lung Cancer AJCC v8
Recurrent Lung Small Cell Carcinoma
Drug: Temozolomide
Biological: Atezolizumab

Phase 2

Dwight Owen

Indianapolis, Indiana, United States and 4 other locations

Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-12)

This Phase 3 study will evaluate the efficacy of the investigational agent MRTX849 (adagrasib) versus docetaxel in patients who have been previously...

Active, not recruiting
Advanced Non Small Cell Lung Cancer
Metastatic Non Small Cell Lung Cancer
Drug: Docetaxel
Drug: MRTX849

Phase 3

Mirati Therapeutics
Mirati Therapeutics

Indianapolis, Indiana, United States and 227 other locations

Pembrolizumab + Imprime PGG for Metastatic Non-small Cell Lung Cancer After Progression on First-Line Therapy: Big Ten Cancer Research Consortium BTCRC-LUN15-017

This is an open label, multi-institutional, single arm study with a dose escalation phase Ib cohort, followed by a phase II cohort of pembrolizumab a...

Active, not recruiting
Non-Small Cell Lung Cancer
Drug: MK-3475
Drug: Imprime PGG

Phase 1, Phase 2

Lawrence Feldman, MD

Indianapolis, Indiana, United States and 4 other locations

Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)

The study is a prospective, randomized controlled phase III trial aimed to test the efficacy and safety of TTFields, using the NovoTTF-200T device, c...

Active, not recruiting
Nonsmall Cell Lung Cancer
NSCLC
Drug: Immune checkpoint inhibitors or docetaxel
Device: NovoTTF-200T

Phase 3

NovoCure
NovoCure

Indianapolis, Indiana, United States and 123 other locations

A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer

This is an open-label Phase I/II study, with a dose escalation part (Phase I) and a single-arm part (Phase II), in patients with recurrent SCLC who p...

Active, not recruiting
Lung Cancer
SCLC
Drug: Nivolumab
Drug: Plinabulin

Phase 1, Phase 2

Salma Sabbour

Indianapolis, Indiana, United States and 7 other locations

Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer

of previously-untreated patients with extensive stage small cell lung cancer. Patients will receive initial chemo-immunotherapy fol...

Enrolling
Extensive Stage Small Cell Lung Cancer
Drug: Etoposide
Drug: Durvalumab

Phase 2

Muhammad Furqan

Indianapolis, Indiana, United States and 4 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2024 Veeva Systems